Your session is about to expire
← Back to Search
KSI-301 for Retinal Vein Occlusion (BEACON Trial)
BEACON Trial Summary
This trial will compare the effectiveness of a new drug, KSI-301, to aflibercept in people with macular edema due to BRVO or CRVO.
- Retinal Vein Occlusion
- Macular Edema
BEACON Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowBEACON Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 4 trial • 26 Patients • NCT03022292BEACON Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What are the main conditions that KSI-301 is used to treat?
"KSI-301 is an effective medical intervention for treating wet age-related macular degeneration (wamd), macular edema, and diabetic macular edema (dme)."
In how many different medical centers is this research project being conducted?
"There are 4 primary locations for this trial: Retina Associates of Western NY in Rochester, New york, Northwest Arkansas Retina Associates in Springdale, Arkansas, and Retina Consultants of San Diego in Poway, California. In addition, there are 99 other sites nationwide."
Are there any available openings for new participants in this clinical trial?
"Unfortunately, this study is not currently enrolling patients. The listing for this trial was first posted on September 25th 2020 and updated as recently as July 20th 2022. There are 133 other trials related to branch vein occlusion that are still recruiting participants and 51 studies involving KSI-301."
Can you provide more context on KSI-301 and its medical applications?
"KSI-301 was first studied in 2013 at the prestigious Massachusetts General Hospital. In the years since, there have been a total of 251 completed trials worldwide. As of now, 51 studies are actively recruiting patients; many of these trials are based in Rochester, New york."
Has KSI-301 passed government regulation for public consumption?
"KSI-301 was given a safety rating of 3 by our team at Power. This is because KSI-301 is currently in Phase 3 clinical trials, which means that there is both some data supporting efficacy and multiple rounds of data supporting safety."
How many people will be included in this clinical trial?
"This study has already completed recruitment for participants. The trial first posted on September 25th, 2020 and was last updated on July 20th, 2022. However, there are 133 clinical trials actively searching for participants with branch vein occlusion and 51 studies for KSI-301 that are still recruiting patients."
Who else is applying?
What state do they live in?
How old are they?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger